CXCR2 and neoplasm: The development of inflammatory niches, in which MAPK inhibition amplifies the release of IL1β by tumor-associated macrophages, mediates the production of a CXC chemokine receptor 2 (CXCR2)-driven secretome by fibroblasts, which in turn promotes melanoma cell survival [90].